A randomized trial comparing preservation of function status after either Medpulser electroporation with intratumoral bleomycin therapy [Selective Electrochemical Tumor Ablation, SECTA; Inovio Biomedical Corporation] or surgery in patients with locally recurrent or second primary squamous cell carcinoma of the base of the tongue, posterior lateral pharyngeal wall, hypopharnyx, or larynx that have failed primary curative therapy

Trial Profile

A randomized trial comparing preservation of function status after either Medpulser electroporation with intratumoral bleomycin therapy [Selective Electrochemical Tumor Ablation, SECTA; Inovio Biomedical Corporation] or surgery in patients with locally recurrent or second primary squamous cell carcinoma of the base of the tongue, posterior lateral pharyngeal wall, hypopharnyx, or larynx that have failed primary curative therapy

Suspended
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2012

At a glance

  • Drugs Bleomycin (Primary)
  • Indications Head and neck cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 23 Jul 2012 Interim results were presented at the 8th International Conference on Head and Neck Cancer in Toronto.
    • 23 Jul 2012 Primary endpoint 'Quality-of-life' has been met.
    • 06 Dec 2007 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top